Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors

长春瑞滨 医学 免疫疗法 曲妥珠单抗 乳腺癌 免疫系统 表位 树突状细胞 免疫学 肿瘤科 T细胞 免疫原性 癌症 癌症疫苗 内科学 抗原 化疗 顺铂
作者
Benjamin Garrett Vincent,Danielle Marie File,Karen P. McKinnon,Dominic T. Moore,Jeffrey A. Frelinger,Edward J. Collins,Joseph G. Ibrahim,Lisa M. Bixby,Shannon Reisdorf,Sonia J. Laurie,Yara A. Park,Carey K. Anders,Frances A. Collichio,Hyman Bernard Muss,LA Carey,Hendrik W. van Deventer,Elizabeth Claire Dees,Jonathan Stuart Serody
出处
期刊:Journal of Immunology [American Association of Immunologists]
卷期号:211 (2): 219-228 被引量:20
标识
DOI:10.4049/jimmunol.2300077
摘要

Previous work from our group and others has shown that patients with breast cancer can generate a T cell response against specific human epidermal growth factor 2 (HER2) epitopes. In addition, preclinical work has shown that this T cell response can be augmented by Ag-directed mAb therapy. This study evaluated the activity and safety of a combination of dendritic cell (DC) vaccination given with mAb and cytotoxic therapy. We performed a phase I/II study using autologous DCs pulsed with two different HER2 peptides given with trastuzumab and vinorelbine to a study cohort of patients with HER2-overexpressing and a second with HER2 nonoverexpressing metastatic breast cancer. Seventeen patients with HER2-overexpressing and seven with nonoverexpressing disease were treated. Treatment was well tolerated, with one patient removed from therapy because of toxicity and no deaths. Forty-six percent of patients had stable disease after therapy, with 4% achieving a partial response and no complete responses. Immune responses were generated in the majority of patients but did not correlate with clinical response. However, in one patient, who has survived >14 y since treatment in the trial, a robust immune response was demonstrated, with 25% of her T cells specific to one of the peptides in the vaccine at the peak of her response. These data suggest that autologous DC vaccination when given with anti-HER2-directed mAb therapy and vinorelbine is safe and can induce immune responses, including significant T cell clonal expansion, in a subset of patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
玺月洛离完成签到,获得积分10
刚刚
dola555完成签到,获得积分10
刚刚
傲娇的天真完成签到,获得积分10
1秒前
viti完成签到 ,获得积分10
1秒前
Fairy完成签到 ,获得积分10
1秒前
xyawl425完成签到,获得积分10
2秒前
王献杰完成签到,获得积分10
2秒前
wjw完成签到,获得积分10
2秒前
2秒前
moya完成签到,获得积分10
3秒前
4秒前
拉普兰Z完成签到,获得积分10
4秒前
独步天下完成签到,获得积分10
4秒前
K珑完成签到,获得积分0
4秒前
Leo完成签到,获得积分10
5秒前
天气不错完成签到,获得积分10
5秒前
5秒前
qingli完成签到,获得积分10
5秒前
崔崔完成签到,获得积分10
6秒前
火星上的友卉完成签到,获得积分10
6秒前
今后的应助被Rony采纳,获得10
6秒前
6秒前
冷水鱼完成签到,获得积分10
6秒前
woo完成签到,获得积分10
6秒前
dujianing完成签到,获得积分10
7秒前
明亮小甜瓜完成签到,获得积分10
7秒前
123566完成签到,获得积分10
7秒前
酆百川完成签到,获得积分10
7秒前
7秒前
我是谁的应助被NN采纳,获得30
8秒前
长情天川发布了新的文献求助10
8秒前
猫小免完成签到 ,获得积分10
8秒前
xrkxrk完成签到 ,获得积分0
9秒前
诗兰完成签到 ,获得积分10
9秒前
00202240完成签到,获得积分10
9秒前
自信的小ping子完成签到,获得积分10
9秒前
东郭千愁完成签到,获得积分10
9秒前
XXXXL完成签到,获得积分10
10秒前
大王具足虫完成签到,获得积分0
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464